What is the price target for DHR stock?
30 analysts have analysed DHR and the average price target is 268.58 USD. This implies a price increase of 44.9% is expected in the next year compared to the current price of 185.355.
NYSE:DHR • US2358511028
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DANAHER CORP (DHR).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-29 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-01-29 | Jefferies | Maintains | Buy -> Buy |
| 2026-01-07 | TD Cowen | Maintains | Buy -> Buy |
| 2026-01-05 | Guggenheim | Maintains | Buy -> Buy |
| 2025-12-15 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-09 | Goldman Sachs | Initiate | Buy |
| 2025-12-02 | Morgan Stanley | Initiate | Overweight |
| 2025-10-23 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-22 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-22 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-08 | Rothschild & Co | Downgrade | Buy -> Neutral |
| 2025-10-07 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-09-22 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-23 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-07-23 | UBS | Maintains | Buy -> Buy |
| 2025-07-23 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-23 | Baird | Maintains | Outperform -> Outperform |
| 2025-07-18 | Baird | Maintains | Outperform -> Outperform |
| 2025-07-11 | ScotiaBank | Upgrade | Sector Perform -> Sector Outperform |
| 2025-07-08 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-06-24 | Barclays | Maintains | Overweight -> Overweight |
| 2025-04-23 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-04-23 | UBS | Maintains | Buy -> Buy |
| 2025-04-23 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-04-23 | Baird | Maintains | Outperform -> Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 23.89B -10.33% | 23.875B -0.06% | 24.568B 2.90% | 25.881B 5.34% | 27.477B 6.17% | 29.253B 6.46% | 31.621B 8.09% | 32.28B 2.08% | N/A | N/A | |
| EBITDA YoY % growth | 7.445B -23.70% | 7.561B 1.56% | 7.829B 3.54% | 8.277B 5.72% | 8.953B 8.17% | 9.633B 7.60% | 10.747B 11.56% | 11.614B 8.07% | N/A | N/A | |
| EBIT YoY % growth | 5.279B -29.95% | 5.209B -1.33% | 5.382B 3.32% | 7.335B 36.29% | 7.896B 7.65% | 8.518B 7.88% | 9.784B 14.86% | 10.629B 8.64% | 11.394B 7.20% | 11.964B 5.00% | |
| Operating Margin | 22.10% | 21.82% | 21.91% | 28.34% | 28.74% | 29.12% | 30.94% | 32.93% | N/A | N/A | |
| EPS YoY % growth | 8.52 -22.19% | 7.49 -12.09% | 7.80 4.14% | 8.49 8.87% | 9.21 8.49% | 10.16 10.30% | 11.34 11.62% | 12.45 9.80% | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.96 4.12% | 1.90 5.54% | 2.01 6.50% | 2.47 10.97% | 2.20 12.49% | 2.14 12.89% | 2.17 7.71% | 2.77 12.11% |
| Revenue Q2Q % growth | 6.063B 5.61% | 6.226B 4.89% | 6.282B 3.78% | 7.182B 5.03% | 6.462B 6.58% | 6.622B 6.36% | 6.663B 6.06% | 7.643B 6.42% |
| EBITDA Q2Q % growth | 1.919B 2.07% | 1.883B -4.03% | 1.952B -34.45% | 2.395B -39.57% | 2.127B 10.84% | 2.08B 10.46% | 2.1B 7.58% | 2.626B 9.65% |
| EBIT Q2Q % growth | 1.676B 30.02% | 1.635B 115.13% | 1.765B 52.95% | 2.189B 44.39% | 1.926B 14.92% | 1.876B 14.74% | 1.894B 7.31% | 2.419B 10.51% |
All data in USD
30 analysts have analysed DHR and the average price target is 268.58 USD. This implies a price increase of 44.9% is expected in the next year compared to the current price of 185.355.
DANAHER CORP (DHR) will report earnings on 2026-04-20, before the market open.
The consensus EPS estimate for the next earnings of DANAHER CORP (DHR) is 1.96 USD and the consensus revenue estimate is 6.06B USD.
The consensus rating for DANAHER CORP (DHR) is 84.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.